迈向帕金森病生物标志物时代。

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2024-03-07 DOI:10.1038/s41582-024-00950-2

Nobutaka Hattori

引用次数: 0

摘要

自 20 世纪 30 年代在癌症研究中提出以来，疾病分期概念已成为临床研究和医疗实践中的重要工具。两篇新论文提出了基于α-突触核蛋白病理学的帕金森病及相关疾病的生物分期和分类系统。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Towards the era of biological biomarkers for Parkinson disease

Since its instigation in cancer research in the 1930s, the disease-staging concept has become a crucial tool in clinical research and medical practice. Two new papers have proposed biological staging and classification systems based on α-synuclein pathology for Parkinson disease and related conditions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.